skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: In Vitro and in vivo antitumor effects of pepleomycin alone or in combination with radiation

Journal Article · · Radiat. Res.; (United States)
DOI:https://doi.org/10.2307/3576469· OSTI ID:5355675

Pepleomycin is a derivative of bleomycin, which is less toxic to the host but possesses greater antitumor activity. Experiments are described herein which Chinese hamster V-79 cells in culture and a murine squamous cell carcinoma in vivo have been used to obtain survival curves for pepleomycin alone or in combination with radiation. In both systems the survival curves for pepleomycin alone are diphasic, and this drug proved to be twice as effective as bleomycin. Further, in contrast to bleomycin, which showed simple additivity with radiation, pepleomycin potentiated radiation injury to the tumor cells both in vivo and in vitro. Therefore, pepleomycin may be superior to bleomycin not only in drug therapy but also in combined modality therapy.

Research Organization:
Tohoku Univ. School of Medicine, Sendai, Japan
OSTI ID:
5355675
Journal Information:
Radiat. Res.; (United States), Vol. 102:2
Country of Publication:
United States
Language:
English